SCHEMBL23249507

SCHEMBL23249507

CCc1c(C)nc(-n2nc(C)c(C)c2NC(=O)c2ccccn2)[nH]c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADCY8 P40145 1/20 0.51
▸ ADCY1 Q08828 1/20 0.51
▸ SLC2A1 P11166 2/20 0.49
▸ POLB P06746 1/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ TSHR P16473 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ GLA P06280 1/20 0.43
▸ TNKS2 Q9H2K2 1/20 0.41
▸ KDM4E B2RXH2 3/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ DCTPP1 Q9H773 2/20 0.40
▸ SPR P35270 2/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ TAS2R8 Q9NYW2 1/20 0.38
▸ MITF O75030 1/20 0.38
▸ PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23249308 0.88 SLC2A1 (0.52) ADCY8ADCY1SLC2A1POLBMEN1
SCHEMBL23249726 0.86 SLC2A1 (0.49) ADCY8ADCY1SLC2A1POLBMEN1
SCHEMBL23249441 0.84 SLC2A1 (0.49) ADCY8ADCY1SLC2A1POLBMEN1
SCHEMBL23249650 0.84 ADCY1 (0.49) ADCY8ADCY1SLC2A1POLBMEN1
SCHEMBL23249463 0.84 SLC2A1 (0.48) ADCY8ADCY1SLC2A1POLBMEN1
SCHEMBL23249648 0.83 ADCY1 (0.73) ADCY8ADCY1SLC2A1
SCHEMBL23259342 0.83 SLC2A1 (0.47) ADCY8ADCY1SLC2A1POLBMEN1
SCHEMBL23249654 0.83 SLC2A1 (0.47) ADCY8ADCY1SLC2A1POLBMEN1
SCHEMBL23249431 0.82 SLC2A1 (0.47) ADCY8ADCY1SLC2A1POLBMEN1
SCHEMBL23259439 0.82 SLC2A1 (0.47) ADCY8ADCY1SLC2A1POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240139190-A1 NOVEL ANTIPARASITIC COMPOUNDS AND METHODS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2024-05-02 — — US disclosed
WO-2021077102-A1 NOVEL ANTIPARASITIC COMPOUNDS AND METHODS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-04-22 — — WO disclosed
WO-2021077102-A1 NOVEL ANTIPARASITIC COMPOUNDS AND METHODS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240139190-A1 NOVEL ANTIPARASITIC COMPOUNDS AND METHODS TUBB, TUBB1, TUBA1C ADCY8 4219/4885ADCY1 4578/4885SLC2A1 4433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback